ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital

Subscribe

08 Apr 2021 18:30 CEST

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date	Number of shares outstanding	Total voting rights
Total gross (1)	Total net (2)
March 31, 2021	24 642 664	24 642 664	24 410 678

(1) The total number of gross (or 'theoretical') voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or 'exercisable at a Shareholders' Meeting') voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of metabolic diseases as well as with a HDL targeted drug delivery platform.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005765/en/

NewCap
Investor relations
Louis-Victor Delouvrier
[email protected]
+33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
[email protected]
+33 (0)1 44 71 94 98

Source

ABIONYX

Provider

BusinessWire